5-HT2A agonists for use in treatment of depression

A method of treating major depressive disorder (MDD) (also known as clinical depression, unipolar depression), melancholia, psychotic depression, antenatal depression, postnatal depression, bipolar disorder, bipolar type I disorder, bipolar type II disorder, cyclothymic disorder, dysthymic disorder or seasonal affective disorder, treatment-resistant depression disorder (TRD), severe treatment-resistant depression disorder, Alzheimer's disease, Parkinson's disease, autism, general anxiety, existential anxiety, end of life anxiety, terminal cancer related end of life anxiety, epilepsy, sleep-wake disorders, neurocognitive disorders, obsessive compulsive disorder (OCD), attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), stress, acute stress disorder, Horton's headache, chronic cluster headache, migraine, general local inflammation, muscle inflammation, joint inflammation, pulmonary inflammation, asthma, arthritis, smoking cessation, alcohol cessation, cocaine cessation, heroin cessation, opioid cessation, methamphetamine cessation, general addiction therapy, eating disorders such as compulsive eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorder, Pica, Rumination disorder, avoidant/restrictive food intake disorder, night eating syndrome, other specified feeding or eating disorder (OSFED), body dysmorphic disorder, purging disorder, pain, chronic pain disorders, sleep wake disorders or physical rehabilitation comprising:

• administering an effective amount of a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof;
• wherein formula (I) has the structure,
• wherein:
• * denotes the (R) or (5) stereoisomer or any mixture thereof;
• X is selected from the group consisting of F, Cl, Br, I, CN, S—(C1-C5 alkyl), S—(C1-C5 fluoroalkyl), S—(C2-C5 alkenyl), S—(C2-C5 fluoroalkenyl), S—(C2-C5 alkynyl), S—(C2-C5 fluoroalkynyl), C1-C5 alkyl, C1-C5 fluoroalkyl, C2-C5 alkenyl, C2-C5 fluoroalkenyl, C2-C5 alkynyl, and C2-C5 fluoroalkynyl;
• Y1 and Y2 are independently selected from the group consisting of H, O, S, C1-C3 alkyl, C1-C3 fluoroalkyl, and halogen;
• R1 is not present when Y1 is H, C1-C3 alkyl, C1-C3 fluoroalkyl, or halogen;
• R2 is not present when Y2 is H, C1-C3 alkyl, C1-C3 fluoroalkyl, or halogen;
• when present, R1 and R2 are independently selected from the group consisting of C1-C5 alkyl, C1-C5 fluoroalkyl, C2-C5 alkenyl, C2-C5 fluoroalkenyl, C2-C5 alkynyl, C2-C5 fluoroalkynyl, C3-C5 cycloalkyl, and C3-C5 fluorocycloalkyl;
• z denotes the number of R3 groups and is an integer with a value of 0, 1, 2, or 3;
• each R3 is independently selected from the group consisting of F, C1-C3 alkyl, C1-C3 fluoroalkyl, C2-C3 alkenyl, and C1-C3 alkynyl;
• and
• R4 is H or CH3;
• with the proviso that at least one of Y1 or Y2 is selected as O or S.